Bicycle Therapeutics PLC
NASDAQ:BCYC

Watchlist Manager
Bicycle Therapeutics PLC Logo
Bicycle Therapeutics PLC
NASDAQ:BCYC
Watchlist
Price: 14.73 USD 0.34%
Market Cap: 1B USD
Have any thoughts about
Bicycle Therapeutics PLC?
Write Note

Bicycle Therapeutics PLC
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bicycle Therapeutics PLC
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Bicycle Therapeutics PLC
NASDAQ:BCYC
Cash from Financing Activities
$519.9m
CAGR 3-Years
58%
CAGR 5-Years
44%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Cash from Financing Activities
$21.1m
CAGR 3-Years
149%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Cash from Financing Activities
-ÂŁ3.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Cash from Financing Activities
-$883k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Cash from Financing Activities
ÂŁ34.3m
CAGR 3-Years
-33%
CAGR 5-Years
221%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Cash from Financing Activities
-ÂŁ2.8m
CAGR 3-Years
42%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Bicycle Therapeutics PLC
Glance View

Market Cap
1B USD
Industry
Biotechnology

Bicycle Therapeutics PLC, a pioneering force in biotechnology, was founded on a unique vision to transform medicine using a novel class of therapeutics known as Bicycles®. These are synthetic short peptides that combine the pharmacological capabilities of biologics with the manufacturing and distribution advantages of small molecules. The company's scientific ingenuity, originating from Cambridge, UK, has enabled it to engineer and develop a pipeline of drugs targeting areas with significant unmet medical needs, primarily in oncology and other severe diseases. Bicycle leverages its distinctive platform technology to design therapeutic candidates that offer high specificity and affinity, focusing on targets that have traditionally been challenging for conventional biologics and small molecules. Monetizing this innovative biotechnology hinges on Bicycle's strategic partnerships and collaborations with major pharmaceutical firms. These alliances allow the company to amplify its reach while sharing the risks and costs associated with drug development. By licensing their Bicycle® technology and therapeutic candidates to larger entities, Bicycle benefits from milestone payments and royalty streams, creating a sustainable revenue model. The company's revenue stream is thus a blend of upfront payments for access to their platform technology and the potential downstream success of these partners in developing and commercializing new therapeutic agents. Their unique approach and strong collaboration network position Bicycle Therapeutics at the forefront of next-generation drug discovery, striving to reshape treatment paradigms across multiple therapeutic areas.

BCYC Intrinsic Value
9.02 USD
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Bicycle Therapeutics PLC's Cash from Financing Activities?
Cash from Financing Activities
519.9m USD

Based on the financial report for Sep 30, 2024, Bicycle Therapeutics PLC's Cash from Financing Activities amounts to 519.9m USD.

What is Bicycle Therapeutics PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
44%

Over the last year, the Cash from Financing Activities growth was 103%. The average annual Cash from Financing Activities growth rates for Bicycle Therapeutics PLC have been 58% over the past three years , 44% over the past five years .

Back to Top